Karl D. Lewis, MD, on the Role of Adjuvant Immunotherapy in NMSC

Posted: Monday, September 23, 2019

What is the future role for adjuvant treatment with cemiplimab, particularly in high-risk groups of patients with nonmelanoma skin cancer?